Dubai Telegraph - Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

EUR -
AED 4.21368
AFN 72.855364
ALL 93.681895
AMD 422.469301
ANG 2.054237
AOA 1052.706336
ARS 1648.454913
AUD 1.633555
AWG 2.065248
AZN 1.949531
BAM 1.933505
BBD 2.31204
BDT 140.916347
BGN 1.940049
BHD 0.432674
BIF 3431.75376
BMD 1.14736
BND 1.470642
BOB 7.961201
BRL 5.840981
BSD 1.147963
BTN 108.494964
BWP 15.381637
BYN 3.178153
BYR 22488.256
BZD 2.308778
CAD 1.620422
CDF 2661.875339
CHF 0.921558
CLF 0.025822
CLP 1016.285446
CNY 7.753228
CNH 7.769761
COP 3941.1816
CRC 522.870871
CUC 1.14736
CUP 30.40504
CVE 109.400865
CZK 23.86744
DJF 203.908666
DKK 7.38457
DOP 67.235231
DZD 152.460019
EGP 57.262669
ERN 17.2104
ETB 181.713165
FJD 2.562859
FKP 0.856464
GBP 0.86653
GEL 3.034766
GGP 0.856464
GHS 12.962529
GIP 0.856464
GMD 83.756918
GNF 10070.951271
GTQ 8.75018
GYD 240.131092
HKD 8.992377
HNL 30.631296
HRK 7.532759
HTG 149.921285
HUF 344.953373
IDR 20364.033696
ILS 3.372401
IMP 0.856464
INR 108.206946
IQD 1503.0416
IRR 1577619.999934
ISK 142.651305
JEP 0.856464
JMD 181.556505
JOD 0.8135
JPY 183.879355
KES 148.606271
KGS 100.336358
KHR 4603.774043
KMF 487.627784
KPW 1032.624402
KRW 1734.653423
KWD 0.3535
KYD 0.956669
KZT 559.819939
LAK 25276.340575
LBP 102746.088062
LKR 384.578843
LRD 208.991429
LSL 18.581332
LTL 3.387856
LVL 0.694026
LYD 7.314443
MAD 10.607363
MDL 20.032014
MGA 4818.911941
MKD 60.909485
MMK 2409.393803
MNT 4106.839908
MOP 9.262002
MRU 45.986241
MUR 54.075353
MVR 17.738466
MWK 1991.817255
MXN 19.921933
MYR 4.663794
MZN 73.318719
NAD 18.589431
NGN 1559.399523
NIO 42.004964
NOK 11.141955
NPR 173.590843
NZD 1.987907
OMR 0.441158
PAB 1.147963
PEN 3.915378
PGK 5.034329
PHP 69.269576
PKR 319.308208
PLN 4.185191
PYG 7005.224033
QAR 4.176967
RON 5.171193
RSD 115.964885
RUB 83.724633
RWF 1707.27168
SAR 4.304773
SBD 9.249356
SCR 16.195128
SDG 688.988904
SEK 10.961654
SGD 1.47095
SHP 0.85662
SLE 28.397494
SLL 24059.569724
SOS 655.724876
SRD 42.833274
STD 23748.035489
STN 24.553504
SVC 10.044269
SYP 126.820108
SZL 18.583652
THB 37.328785
TJS 10.641495
TMT 4.027234
TND 3.340826
TOP 2.762568
TRY 53.28921
TTD 7.798082
TWD 36.208963
TZS 3011.823408
UAH 51.411926
UGX 4247.028287
USD 1.14736
UYU 46.345997
UZS 13774.056637
VES 683.86832
VND 30205.39936
VUV 136.523105
WST 3.143481
XAF 648.479501
XAG 0.01722
XAU 0.00027
XCD 3.100798
XCG 2.068926
XDR 0.807394
XOF 648.258605
XPF 119.331742
YER 273.788809
ZAR 18.824495
ZMK 10327.618428
ZMW 20.290039
ZWL 369.449452
  • RBGPF

    -1.7300

    61.14

    -2.83%

  • RYCEF

    -0.5900

    18

    -3.28%

  • AZN

    -3.0300

    174.86

    -1.73%

  • NGG

    -1.4600

    79.22

    -1.84%

  • GSK

    -1.2800

    50.87

    -2.52%

  • RIO

    -2.4500

    100.22

    -2.44%

  • CMSC

    0.1050

    22.425

    +0.47%

  • RELX

    -0.7400

    31.27

    -2.37%

  • BCE

    0.0450

    23.325

    +0.19%

  • VOD

    -0.2150

    14.315

    -1.5%

  • BCC

    4.9800

    75.79

    +6.57%

  • BTI

    -0.8600

    58.63

    -1.47%

  • BP

    -1.2750

    38.865

    -3.28%

  • JRI

    0.1180

    12.738

    +0.93%

  • CMSD

    0.0450

    22.335

    +0.2%

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives
Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

  • Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations

  • Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization

  • Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks

Text size:

TAMPA, FL / ACCESS Newswire / April 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced the execution of a definitive joint venture agreement with Kare PharmTech's wholly owned subsidiary, Kare Rx Hub, LLC ("KareRx"), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and specialty pharmaceutical programs.

The execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone in aligning both organizations' technology platforms and operational teams into a unified ecosystem designed to accelerate patient access and improve the efficiency of pharmaceutical commercialization. By integrating the Wellgistics Hub technology stack including proprietary platforms EinsteinRx™ and HubRx AI™ with KareRx's digital hub, the combined platform is positioned to streamline the prescription journey from intake through fulfillment.

Prashant Patel, Chief Executive Officer of Wellgistics Health, commented, "This joint venture reflects our continued focus on building an integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies. By combining KareRx's provider connectivity and digital engagement capabilities with our infrastructure, we believe this collaboration enhances operational efficiency and supports manufacturers and other healthcare stakeholders in navigating access pathways more effectively."

The joint venture aligns clinical, operational, and commercial teams across both organizations, enabling more seamless coordination between providers, pharmacies, and patients. Through this integration, the platform enhances key capabilities including eligibility and benefits verification, prior authorization workflows, prescription routing, and direct-to-patient fulfillment. The combined ecosystem includes a growing national footprint of independent pharmacies, provider networks, and telehealth channels, with the ability to reach more than 200,000 patient lives based on third-party internal estimates.

Mital Panera, Founder and Chief Executive Officer of KareRx, added, "KareRx was developed to connect providers, pharmacies, and patients through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics' technology stack, pharma expertise, and operational infrastructure. We believe the combined platform will support improved connectivity across stakeholders and facilitate access to therapies across participating networks."

The collaboration further strengthens direct-to-patient (DTP) and decentralized care models, providing pharmaceutical manufacturers with a comprehensive platform that integrates access, affordability, and fulfillment into a single solution. Leveraging AI-driven insights and a fully integrated operational backbone, the joint venture is designed to reduce barriers to therapy initiation, improve adherence, and deliver enhanced visibility into patient access and program performance.

The joint venture remains subject to customary implementation steps, and there can be no assurance regarding the timing or extent of operational integration or the realization of anticipated benefits. Additional details regarding the joint venture agreement will be provided in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

About Kare PharmTech, LLC

Kare Rx Hub is an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal, and specialty pharmaceutical 'lite' branded products with over 500 physician-provider relationships, 200 independent pharmacy relationships that market unique specialty pharmaceutical 'lite' products. Kare Rx Hub is owned by Kare Pharmtech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Wellgistics Media & Investor Contact
Media: [email protected]
Investor Relations: [email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

R.El-Zarouni--DT